content_image/261591.jpg content_image/261592.jpg content_image/261593.jpg content_image/261594.jpg
## prOduCT pOrTfOliO TO SuppOrT GrOwTh 

(*Sales are shown based on ifrS) 

In highly specialized therapeutic areas including urology and transplantation, Astellas has created innovative new drugs such as overactive bladder (OAB) treatments and an immunosuppressant, and has established a global competitive advantage. 

## Mainstay Products in Urology 

<img src='content_image/261591.jpg'>

## Fiscal 2013 sales: ¥133.8 billion 

Vesicare is a treatment for OAB that helps to relieve associated symptoms such as urinary urgency, frequent urination and urinary incontinence. Launched in Europe in 2004, it is now sold in approximately 80 countries and regions. 

<img src='content_image/261592.jpg'>

## Fiscal 2013 sales: ¥28.2 billion 

This is an OAB treatment with a different mechanism of action from Vesicare. After its initial launch in Japan in 2011 with the brand name of Betanis, the product has been successively launched in the U.S. and in Europe with the brand name of Myrbetriq and BETMIGA, respectively. It is currently sold in over 25 countries and regions. 

## Mainstay Products in Immunology (including Transplantation) and Infectious Diseases 

<img src='content_image/261593.jpg'>

## Fiscal 2013 sales: ¥181.1 billion 

This product is an immunosuppressant used to sup- press organ rejection in organ transplants. It is sold in approximately 100 countries and regions and has made a significant global contribution to the field of transplantation. 

<img src='content_image/261594.jpg'>

## Fiscal 2013 sales: ¥36.1 billion 

This product is a candin-type antifungal agent that treats fungal infections with a mechanism of action that inhibits cell wall biosynthesis. It is sold in approximately 50 countries and regions. 

